Clinical Trial Update: Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sorafenib and erlotinib in locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Hilar Cholangiocarcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-29